[go: up one dir, main page]

WO2013066469A3 - Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics - Google Patents

Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics Download PDF

Info

Publication number
WO2013066469A3
WO2013066469A3 PCT/US2012/050635 US2012050635W WO2013066469A3 WO 2013066469 A3 WO2013066469 A3 WO 2013066469A3 US 2012050635 W US2012050635 W US 2012050635W WO 2013066469 A3 WO2013066469 A3 WO 2013066469A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacterial pathogens
lactam antibiotics
disclosed
sensitivity
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/050635
Other languages
French (fr)
Other versions
WO2013066469A2 (en
Inventor
Lakshmi Rajagopal
Kellie Burnside HOWARD
Christopher WHIDBEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of WO2013066469A2 publication Critical patent/WO2013066469A2/en
Publication of WO2013066469A3 publication Critical patent/WO2013066469A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Staphylococcus aureus are gram-positive bacteria that are currently the leading cause of invasive infections in humans. While antibiotic therapy is currently used to treat S. aureus infections, the emergence of antibiotic resistant strains such as those resistant to methicillan are rapidly exhausting treatment options. Disclosed herein are methods and compositions for increasing the sensitivity of bacterial pathogens to β-lactam antibiotics. Also disclosed herein are genes involved in modulating antibiotic resistance which serve as novel targets for treatments aimed at inhibiting antibiotic resistant bacterial pathogens. Also disclosed herein are kinase inhibitors which demonstrate superior activity in sensitizing bacterial pathogens to β-lactam antibiotics.
PCT/US2012/050635 2011-08-15 2012-08-13 Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics Ceased WO2013066469A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161523793P 2011-08-15 2011-08-15
US61/523,793 2011-08-15

Publications (2)

Publication Number Publication Date
WO2013066469A2 WO2013066469A2 (en) 2013-05-10
WO2013066469A3 true WO2013066469A3 (en) 2013-07-04

Family

ID=48192985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/050635 Ceased WO2013066469A2 (en) 2011-08-15 2012-08-13 Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics

Country Status (1)

Country Link
WO (1) WO2013066469A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015075166A1 (en) * 2013-11-22 2015-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of a bacterial infection
IL307873A (en) * 2021-04-22 2023-12-01 Kayothera Inc Heterocyclic compounds and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060070135A1 (en) * 1998-07-24 2006-03-30 Michel Tremblay Compositions and methods for inhibiting the enzymatic activity of PTP-1B
WO2007075176A1 (en) * 2005-12-29 2007-07-05 Mitsui Norin Co., Ltd Compositions and methods of sensitizing methicillin resistant staphylococcus aureus to oxacillin
US20080312244A1 (en) * 2005-07-29 2008-12-18 Werner Mederski Squaric Acid Derivatives as Protein Kinase Inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060070135A1 (en) * 1998-07-24 2006-03-30 Michel Tremblay Compositions and methods for inhibiting the enzymatic activity of PTP-1B
US20080312244A1 (en) * 2005-07-29 2008-12-18 Werner Mederski Squaric Acid Derivatives as Protein Kinase Inhibitors
WO2007075176A1 (en) * 2005-12-29 2007-07-05 Mitsui Norin Co., Ltd Compositions and methods of sensitizing methicillin resistant staphylococcus aureus to oxacillin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RENZONI ET AL.: "Whole Genome Sequencing and Complete Genetic Analysis Reveals Novel Pathways to Glycopeptide Resistance in Staphylococcus aureus, art e21577", PLOS ONE, vol. 6, no. 6, 27 June 2011 (2011-06-27), pages 1 - 14, XP003031273 *
ZAPUN ET AL.: "Penicillin-Binding Proteins and Beta-Lactam Resistance", ANTIMICROBIAL DRUG RESISTANCE, vol. 1, 2009, pages 145 - 170 *

Also Published As

Publication number Publication date
WO2013066469A2 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
WO2013122888A3 (en) Methods of treating bacterial infections
WO2018208985A3 (en) Antibacterial compounds
AU2012302022A8 (en) Antibacterial compounds and methods for use
PH12016501577B1 (en) Monobactam organic compounds for the treatment of bacterial infections
WO2016179440A3 (en) Antimicrobial therapy
WO2018208987A3 (en) Antibacterial compounds
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
WO2013184755A3 (en) Seca inhibitors and methods of making and using thereof
WO2009140215A3 (en) Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
TN2014000417A1 (en) Heterobicyclic compounds as beta-lactamase inhibitors
PH12019500360A1 (en) Antibiotic compounds
WO2015114666A3 (en) Treatments for resistant acne
HK1199693A1 (en) Antibacterial compounds and methods for use
WO2017017631A3 (en) Antibacterial therapeutics and prophylactics
WO2012173689A3 (en) Antimicrobial compounds and methods of making and using the same
WO2012034077A3 (en) Compositions and methods related to attenuated staphylococcal strains
GB0813211D0 (en) Antibacterial combination therapy for the treatment of gram positive bacterial infections
WO2012106264A3 (en) Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
MX2021003084A (en) Antibacterial compounds.
MX2011008043A (en) Actagardine derivatives.
WO2014022382A3 (en) Antibacterial protein kinase inhibitors
HK1201836A1 (en) Novel pyrrole derivatives
AU2010306647A8 (en) Antimicrobial compounds and methods of making and using the same
MX2021001564A (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases.
WO2016108930A3 (en) Antisense antibacterial compounds and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12844682

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12844682

Country of ref document: EP

Kind code of ref document: A2